LSD1-targeted therapy—a multi-purpose key to unlock immunotherapy in small cell lung cancer
Translational Lung Cancer Research · 2023-06 · 12 (6) · 1350-1354
DOI: 10.21037/tlcr-23-40 ↗Kurz gefasst
Editorial in der Zeitschrift Translational Lung Cancer Research, 2023-06. Verfasst von Martin Sattler und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Die Arbeit wurde bisher 10-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
- Department of Medicine, Harvard Medical School, Boston, MA, USA.
- Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA.
Zitieren
APA
Sattler, M., & Salgia, R. (2023). LSD1-targeted therapy—a multi-purpose key to unlock immunotherapy in small cell lung cancer. Translational Lung Cancer Research, 12(6), 1350-1354. https://doi.org/10.21037/tlcr-23-40
Vancouver
Sattler M, Salgia R. LSD1-targeted therapy—a multi-purpose key to unlock immunotherapy in small cell lung cancer. Translational Lung Cancer Research. 2023;12(6):1350-1354. doi:10.21037/tlcr-23-40
BibTeX
@article{Sattler2023,
author = {Sattler, Martin and Salgia, Ravi},
title = {LSD1-targeted therapy—a multi-purpose key to unlock immunotherapy in small cell lung cancer},
journal = {Translational Lung Cancer Research},
year = {2023},
volume = {12},
number = {6},
pages = {1350--1354},
doi = {10.21037/tlcr-23-40}
}
EUVIMED